FDA Brief

Warning letters Drugs

FDA warning letter to

Disinfect & Shield

High riskIssued May 6, 2021Posted May 7, 2021Center for Drug Evaluation and Research

FDA warned Disinfect & Shield that its non-alcohol hand sanitizer was an unapproved drug sold with COVID-19 and long-lasting efficacy claims.

What happened

FDA reviewed the company website on May 5, 2021. It found DISINFECT™ & SHIELD HAND SANITIZER offered for sale with claims that it kills COVID-19, protects for up to 8 hours, and is effective against pathogens such as SARS, H1N1, and Ebola. FDA cited the product as an unapproved new drug and as misbranded (misleadingly labeled), including misleading “FDA Listed” and “FDA Registered” statements.

What FDA found

  1. The hand sanitizer was sold as a new drug without FDA approval, based on website claims that it prevents or treats COVID-19 and other diseases.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. FDA found no adequate and well-controlled clinical studies showing the product is generally recognized as safe and effective for its claimed uses.

    section 201(p) of the FD&C Act, 21 U.S.C. § 321(p)
  3. The product's labeling claimed specific disease kill and up to 8-hour protection beyond the allowed over-the-counter antiseptic uses, so it did not meet the conditions for marketing under section 505G.

    section 505G(a)(3) of the FD&C Act, 21 U.S.C. § 355h(a)(3)
  4. The website used “FDA Listed” with FDA's logo and “FDA Registered” in a way that falsely suggested FDA approval or endorsement.

    section 502(a) of the FD&C Act, 21 U.S.C. § 352(a); 21 CFR 207.77(a)
  5. The product was misbranded because it was subject to section 505G but did not meet that section's marketing requirements and had no approved application.

    section 502(ee) of the FD&C Act, 21 U.S.C. § 352(ee)

What FDA wants

FDA tells the company to take immediate action to stop selling unapproved products for COVID-19 and to review websites, labels, and promotional materials. Within 48 hours, the company must email FDA describing steps taken, how it will prevent recurrence, and related documentation.

Who should pay attention

  • hand sanitizer brands and marketers
  • online retailers and marketplaces selling OTC antiseptics
  • companies making COVID-19 or antiviral claims for topical products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk